๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› HNSCC
Clinical trial register · China

HNSCC Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 7 Chengdu 5 Beijing 3 Shanghai 3 Hefei 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou7 Chengdu5 Beijing3 Shanghai3 Hefei1
All 14 locations
Target enrolment
to

HNSCC trials in China

16 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
NCT07668154HNSCC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chengdu, Shanghai
2026-07-27
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Not yet open
Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial
NCT07491783HNSCC, Soft Tissue Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 2
52
Chengdu
2026-03-27
Recruiting
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
NCT07686575HNSCC, OSCC, OPSCC, Ivonescimab
Zhujiang Hospital
Observational
20
Guangzhou
2026-01-26
Recruiting
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
NCT07035249DCSZ11, Solid Tumors, HNSCC
DrugDCSZ11
West China Hospital
Phase 1/2
9
Chengdu
2025-12-16
Recruiting
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
NCT07081984HPV 16+ Recurrent or Metastatic Cancer, HNSCC, Cervical Cancer
Therorna
Phase 1
12
Shanghai
2025-11-11
Recruiting
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
NCT07040072HNSCC
Beijing Tongren Hospital
Phase 1
10
Beijing
2025-10-09
Not yet open
PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)
NCT07090707HNSCC, PD-1, Radiotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
50
Guangzhou
2025-08-01
Active, closed
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
NCT06673693Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC
Sun Yat-sen University
Phase 2
24
Guangzhou
2025-06-25
Active, closed
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
NCT07010120HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1/2
29
Chengdu
2025-06-10
Recruiting
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
NCT06741982HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1
21
Chengdu
2024-12-15
Active, closed
Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma ๏ผˆHNC-SYSU-005๏ผ‰
NCT07267286HNSCC, PD-1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
60
Guangzhou
2024-12-15
Recruiting
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
NCT06190275HNSCC
Grit Biotechnology
Not applicable
32
Shanghai
2024-05-12
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
NCT05980702HNSCC, Oral Cancer, PD-1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
192
Guangzhou
2023-04-04
Recruiting
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
NCT05980715HNSCC, Radiotherapy, PD-1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
324
Guangzhou
2023-01-01
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/hnscc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies listing the condition HNSCC.

How many HNSCC trials are recruiting in China?

10 of the 16 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (HNSCC), 16 studies
PhaseStudiesRecruitingShare
Phase 28350%
Phase 13318.8%
Phase 1/22112.5%
Not applicable116.3%
Observational116.3%
Phase 3116.3%

Most active sponsors

Lead sponsors with the most studies (HNSCC)
Lead sponsorStudiesRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University42
West China Hospital32
Beijing Tongren Hospital11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Grit Biotechnology11
MediLink Therapeutics (Suzhou) Co., Ltd.11
Sichuan Enray Pharmaceutical Sciences Company10
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.11
Sun Yat-sen University10
Therorna11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.